Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases.

Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Chemomab Therapeutics Ltd.

Country	Israel
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	Adi George

Contact Details

Address: Building C, 10th Floor Tel Aviv-Yafo, 6158101 Israel
Phone	972 77 331 0156
Website	chemomab.com

Stock Details

Ticker Symbol	CMMB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1534248
CUSIP Number	16385C203
ISIN Number	US16385C2035
Employer ID	81-3676773
SIC Code	2834

Key Executives

Name	Position
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director

Latest SEC Filings

Date	Type	Title
Jul 16, 2026	SCHEDULE 13D	Filing
Jul 8, 2026	6-K	Report of foreign issuer
Jun 2, 2026	6-K	Report of foreign issuer
May 14, 2026	6-K	Report of foreign issuer
May 6, 2026	6-K	Report of foreign issuer
Apr 28, 2026	6-K	Report of foreign issuer
Mar 23, 2026	20-F	Annual and transition report of foreign private issuers
Mar 20, 2026	6-K	Report of foreign issuer
Mar 19, 2026	6-K	Report of foreign issuer
Feb 17, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings